<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547794</url>
  </required_header>
  <id_info>
    <org_study_id>CRD 310</org_study_id>
    <nct_id>NCT00547794</nct_id>
  </id_info>
  <brief_title>AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF</brief_title>
  <acronym>AVERT-AF</acronym>
  <official_title>AVERT-AF: Atrio-VEntricular Junction Ablation Followed by Resynchronization Therapy in Patients With Congestive Heart Failure and Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the combination of AVJ ablation followed by BiV
      pacing significantly improves functional status and exercise capacity compared to
      pharmacologic rate control in patients with chronic AF and depressed ejection fraction,
      regardless of rate or QRS duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a prospective, randomized, double blinded, multicenter study

        -  Patients meeting all the enrollment criteria are screened at enrollment and randomized
           to Group 1 (Pharmacological therapy + Single Chamber ICD) or Group 2 (AVJ Ablation +
           CRT-D)

        -  Screened patients are implanted with a FDA approved SJM ICD/CRT-D with compatible lead
           system

        -  Patients are followed at 1, 3, 6 and 12 months post implant

        -  Total # of centers - 20 centers

        -  Sample size - 180 patients
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in patient enrollment
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise duration</measure>
    <time_frame>12 month post implant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) via Minnesota Living With Heart Failure (MLWH) questionnaire</measure>
    <time_frame>12 month post implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class Progression</measure>
    <time_frame>12 month post implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>12 month post implant</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT-D + AVJ Ablation</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-Chamber ICD + Pharmacological Therapy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with history of permanent AF and CHF
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic permanent AF

          -  Class I or II indication for ICD

          -  LVEF ≤ 35% within 6 months

          -  NYHA class II or III with a history of CHF

          -  Maximal tolerated drug therapy for CHF and rate control with a stable regimen for ≥ 30
             days

          -  Ability to independently comprehend and complete a QoL questionnaire

          -  Ability to give informed consent for study participation and willingness and ability
             to comply with prescribed follow-up tests and scheduled evaluations

        Exclusion Criteria:

          -  Paroxysmal or persistent AF

          -  Class I indication for pacing (including AVJ ablation for poor rate control)

          -  Ability to walk ≥ 450 meters in 6 minutes

          -  Musculoskeletal disorders that prohibit the completion of a 450 meters walk

          -  NYHA class I or IV at the time of enrollment

          -  A contraindication to taking Coumadin therapy

          -  History of myocardial infarction, percutanous coronary intervention, or CABG in the
             past 30 days

          -  History of mitral valve surgery

          -  Prior attempts for cardiac resynchronization therapy

          -  The presence of an existing coronary sinus lead or epicardial lead

          -  Life expectancy &lt; 1year

          -  Age &lt; 18 yrs

          -  Current participation in other clinical studies except registry trials

          -  Use of calcium channel blockers

          -  Pregnancy

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hamdan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hamdan MH, Freedman RA, Gilbert EM, Dimarco JP, Ellenbogen KA, Page RL. Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design. Pacing Clin Electrophysiol. 2006 Oct;29(10):1081-8.</citation>
    <PMID>17038140</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2007</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

